11:30 AM EST - Medicenna Therapeutics Corp. : Will host a Key Opinion Leader call and webcast for the investment community on Tuesday, June 18. The event will be focused on Medicenna's MDNA55 recurrent glioblastoma (rGBM) program which recently completed enrolment and will discuss preliminary top-line tumor response results to be presented at the Inaugural Immuno-Oncology Pharma Congress held on June 18, during World Pharma Week in Boston. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.16 at $1.84.
